Clinical Trial

A MULTICENTER, SEEKING SIGNAL, RANDOMISED, OPEN-LABEL PHASE II OF RELATLIMAB AND NIVOLUMAB VS NIVOLUMAB ALONE IN LOCALLY ADVANCED CERVICAL CANCERS

Study acronym: COLIBRI-2
Active, Not Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
Multicenter, open-label, randomized, seeking signal (non-comparative), Phase II aiming to assess the clinical activity of the combination relatlimab + nivolumab in locally advanced cervical cancer eligible to standard CCRT
Protocol Amendment History 5 amendments
This ClinicalTrials.gov record has been amended 5 times since 2024-12-03; most recent amendment 2026-01-20.
Status change: Recruiting → Active, Not Recruiting 2026-01-20
Status change: Not Yet Recruiting → Recruiting 2025-01-06
Trial Details
NCT Number NCT06715241
Lead Sponsor ARCAGY/ GINECO GROUP
Conditions LOCALLY ADVANCED CERVICAL CANCERS
Enrollment 77 participants
Start Date 2024-12-11
Primary Completion 2030-12-31 (estimated)
Study Completion 2030-12-31 (estimated)
Updated on ClinicalTrials.gov 2026-07-30